Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.35 |
| ▸ | PIK3R2 | O00459 | 14/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.35 |
| ▸ | PIK3R5 | Q8WYR1 | 14/20 | 0.35 |
| ▸ | PIK3R3 | Q92569 | 14/20 | 0.35 |
| ▸ | UGCG | Q16739 | 3/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885924 | 0.91 | GRM5 (0.37) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL17382275 | 0.88 | PIK3CD (0.34) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL27123561 | 0.87 | GRM5 (0.36) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL30759609 | 0.87 | GRM5 (0.36) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL17783226 | 0.87 | PIK3CD (0.36) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL17382281 | 0.86 | PIK3CD (0.32) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL30886053 | 0.86 | GRM5 (0.33) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL17382145 | 0.85 | GRM5 (0.37) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL31236950 | 0.85 | GRM5 (0.37) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL17382270 | 0.85 | PIK3CD (0.35) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | GRM5 1818/4885PIK3CD 4438/4885PIK3R2 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.